Research
Helping develop the next generation of advanced treatments through research is part of our mission at Kadima Neuropsychiatry
Research
Helping develop the next generation of advanced treatments through research is part of our mission at Kadima Neuropsychiatry
Our Research
Kadima Neuropsychiatry conducts clinical trials of cutting-edge, experimental novel treatments for various mental health conditions, including depression and treatment-resistant depression, generalized anxiety disorder, and PTSD. The experimental treatments that are currently, or soon to be, tested at KADIMA, for a variety of psychiatric conditions, include psilocybin, LSD, DMT, alternate form of ketamine, other medications with novel mechanisms of action, innovative medical devices, digital mental health apps, and virtual reality. If you want to learn more about the studies we’re doing, please ask!
Psychedelic Substances We Explore:
LSD
Lysergic acid diethylamide
Psilocybin
“magic mushrooms”
5-MeO-DMT
5-methoxy-N,N-dimethyltryptamine
Active Research
Study assessing LSD for the Treatment of Anxiety Symptoms
Investigational Treatment: This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM-120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD). Learn more about the investigational treatment.
Effects of a Virtual Reality PsyAssist Calm Experience Program on Pre-treatment Anxiety Prior to Ketamine Dosing
Sponsor: TRIPP PsyAssist
Investigational Treatment: TRIPP PsyAssist is a virtual reality meditation program that aims to reduce pre-treatment anxiety in ketamine patients with anxiety symptoms. – Learn more about the investigational treatment
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-II)
Investigational Treatment: REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Learn more about the investigational treatment.
A Study to Assessing a Novel NMDA Receptor Drug for Ongoing Trauma (PTSD)
Investigational Treatment: A randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of 50 mg NYX-783 once daily vs. placebo in participants with post-traumatic stress disorder (PTSD) —. Learn more about the investigational treatment.
Cognitive Behavioral Therapy (CBT) in adjunct with Deep Transcranial Magnetic Stimulation (dTMS) for Major Depressive Disorder (MDD)
Sponsor: Brainsway
Investigational Treatment: CBT-based, mobile-delivered, intervention platform. Learn more about the investigational treatment.
Study assessing an novel NMDA receptor modulator for Major Depressive Disorder
Investigational Treatment: REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Learn more about the investigational treatment.
Study evaluating a Brain Neuromodulation system for the Treatment of Major Depressive Disorder (MDD).
Investigational Treatment: Relivion®DP is a non-invasive and multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders – Learn more about the investigational treatment
Are You Interested in Participating in Clinical Research?
To sign up for potential participation in clinical research studies at Kadima, please fill out the following survey and provide your contact information.
Upcoming Research
Study of Psilocybin for Treatment Resistant Depression
Study of 5MeO-DMT for Treatment Resistant Depression
Recently Completed Trials
1. Compass Pathways, COMP001
The safety and efficacy of psilocybin in participants with Treatment Resistant Depression. Read More
2. Compass Pathways, COMP003
The safety and efficacy Of psilocybin as an adjunctive therapy in participants with Treatment Resistant Depression. Read More
3. Perception Neuroscience, Inc, PCN-101
The safety and efficacy of PCN-101 (R-Ketamine) in participants with Treatment Resistant Depression. Read More
Get in Contact
Address: 3252 Holiday Court, Suite 112 La Jolla, CA 92037
Email: info@kadimanp.com